** Shares of GH Research GHRS.O down 20.5% to $14.30 on Tues as co seeks equity to fund development of its treatments for depression

** GHRS shares surged 70% to close at $17.99 on Mon after co said its depression therapy, GH001, met main goals of mid-stage study

** After the bell Mon, Ireland-based biotech commenced $150 mln stock offering

** It plans to use net offering proceeds to invest in research, clinical and technical development of current and/or additional product candidates, according to the SEC filing

** Cantor, Stifel and RBC acting as jt bookrunners for the offering

** With ~52 mln shares outstanding, co has current market cap of roughly $760 mln

** Stock ended 2024 at $7

** All 5 analysts covering GHRS are bullish with median PT of $37, LSEG data shows

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))